Income Taxes |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes | Income Taxes The Company’s continuing operations tax provision for interim periods is determined using an estimate of the Company’s annual effective tax rate adjusted for discrete interim period tax impacts. Each quarter the Company updates its estimated annual effective tax rate and, if the estimate changes, makes a cumulative adjustment. The Company’s effective tax rate from continuing operations was 10.4% and (101.0)% for the three months ended September 30, 2026 and 2025, respectively, and (0.3)% and 145.4% for the nine months ended September 30, 2026 and 2025, respectively. The Company’s continuing operations effective tax rate was disproportionately impacted by a goodwill impairment of $29.6 million for the three months ended September 30, 2026 and a goodwill impairment of $84.4 million for the nine months ended September 30, 2026, for which only a $1.5 million tax benefit was recorded since the impairment was mostly allocated to the excess financial statement goodwill with no tax basis. During the three and nine months ended September 30, 2025, the Company’s continuing operations effective tax rate was disproportionally impacted by a goodwill impairment of $17.6 million for which no tax benefit was recorded since the impairment was entirely related to excess financial statement goodwill with no tax basis. As of September 30, 2026 and December 31, 2025, in addition to amounts recorded in ‘Liability for uncertain tax positions’, the Company had $0.0 million and $9.1 million, respectively, for uncertain income tax positions from continuing operations in ‘Other current liabilities’ on the Condensed Consolidated Balance Sheets. Accrued interest and penalties related to unrecognized tax benefits associated with uncertain tax positions are recognized in income tax expense in our Condensed Consolidated Statements of Operations. Certain taxes are prepaid during the year and, where appropriate, included within ‘Prepaid expenses and other current assets’ on the Condensed Consolidated Balance Sheets. The Company’s continuing operations prepaid taxes were $0.0 million and $26.2 million as of September 30, 2026 and December 31, 2025, respectively. The Company’s current income tax payable increased from $7.3 million as of December 31, 2025 to $130.8 million as of September 30, 2026 due to the taxes payable related to the gain on the sale of Connectivity. On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law which, among other things, provided a permanent extension of certain tax measures initially established under the 2017 Tax Cuts and Jobs Act, which were set to expire at the end of 2025, and modified tax legislation affecting bonus depreciation rules and the tax treatment of research and development expenses and interest deductions. Specifically, the OBBBA provides for 100% bonus depreciation and eliminates the requirement under Internal Revenue Code Section 174 to capitalize and amortize U.S. based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred beginning after 2024. Income taxes paid, net of refunds from continuing and discontinued operations during the nine months ended September 30, 2026 and 2025 were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||